Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma

NCT00153933 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

58

Enrollment

OTHER

Sponsor class

Conditions

Refractory Multiple Myeloma
Relapsed Multiple Myeloma
Multiple Myeloma

Interventions

DRUG: Bortezomib
DRUG: CC-5013

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]
[object Object]
[object Object]